Phase I/II Study of MLN4924 Alone Followed by Dose-Adjusted EPOCH-Rituximab + MLN4924 With Gene Expression Profiling and Mutational Analysis in Relapsed/Refractory de Novo Diffuse Large B-Cell Lymphoma.
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 19 May 2017
At a glance
- Drugs Pevonedistat (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Filgrastim; Prednisone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 29 Jan 2014 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by clinicalTrials.gov
- 08 Jan 2014 Planned End Date changed from 1 Sep 2015 to 1 Jan 2014.
- 25 Apr 2012 Status changed from suspended to not yet recruiting as reported by ClinicalTrials.gov.